Zentalis Pharmaceuticals has announced a significant advancement in the clinical development of azenosertib, a first-in-class WEE1 inhibitor, following a planned interim analysis from the DENALI Part 2a trial. The analysis identified 400mg QD 5:2 as the optimal monotherapy dose for patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC), demonstrating a differentiated response rate compared to the previously tested 300mg QD 5:2 dose, while maintaining comparable safety profiles across both groups.

The findings underscore the therapeutic potential of azenosertib, particularly in a patient population that currently lacks approved treatment options. The interim analysis revealed a favorable benefit-risk profile, with a marked reduction in the discontinuation rate due to adverse events—approximately half of that seen in earlier DENALI trials—and no treatment-related deaths reported. This data supports the ongoing Phase 2 DENALI and the upcoming Phase 3 ASPENOVA trials, both of which aim to expedite the drug’s path to regulatory approval.

The implications of this development extend to the broader landscape of ovarian cancer treatment. By confirming the 400mg QD 5:2 dosing regimen, Zentalis is not only enhancing the clinical pipeline for azenosertib but also positioning it as a potential oral alternative to traditional intravenous chemotherapy for PROC patients. As enrollment in the expanded cohorts of DENALI Part 2 and ASPENOVA is set to begin in Q2 2026, this strategic move may significantly alter the trajectory of drug development timelines and treatment paradigms for this challenging cancer subtype.

Source: globenewswire.com